No manipulated trial results so no need for more deception leading to wrong information.
DCVax-L works for the most part but there are statistical outers that are based on certain resistive cancer cases which Dr. Linda Liau has already addressed in several presentations. Therefore, Dr. Linda Liau still supports DCVax-L and is not changing her tune at all, IMPO.
Hence, DCVax-L is added with other combinations to address the resistive cancer cases, it is obvious per your comment that "She's now doing combo trials and promoting the value of PDL-1 and immunotherapy. And she's one of the world's leading expert on DCVax.."
Market Data 
Markets 
